Effect of oral livergol on liver enzymes in patients with Leukemia
Phase 3
Recruiting
- Conditions
- eukemia in the Preservative Phase.Leukemia, unspecifiedC95.9
- Registration Number
- IRCT20150119020715N10
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients over 5 years of age with leukemia in the preservative phase referring to Amir Kabir hospital in Arak
Informed consent of the participants in the study
Disrupted liver enzymes (AST and ALT greater than 60).
Total cholesterol above 200
Total bilirubin equal to or greater than 2
GGT more than 60
Exclusion Criteria
With other blood diseases and liver diseases such as HBV, HCV and HIV
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie oral livergol's impact on liver enzymes in leukemia patients during the preservative phase?
How does oral livergol compare to standard-of-care treatments for managing liver enzyme abnormalities in leukemia patients?
Which biomarkers correlate with improved liver enzyme outcomes in IRCT20150119020715N10 leukemia trials?
What adverse events are associated with oral livergol in leukemia patients, and how are they managed clinically?
Are there synergistic combination therapies involving livergol for leukemia in the preservative phase, and what are their efficacy profiles?